Head & Neck Cancer Clinical Trial
— PharyngociseOfficial title:
Muscle Composition and Function for Swallowing in Head/Neck Cancer Patients Undergoing Radiotherapy: a Randomized Controlled Trial of Swallowing Therapy"
Verified date | September 2011 |
Source | University of Florida |
Contact | n/a |
Is FDA regulated | No |
Health authority | United States: Institutional Review Board |
Study type | Interventional |
Swallowing dysfunction after chemo-radiation is common, but there is no reliable evidence for how it should be managed. This pilot randomized controlled trial evaluated the relative benefit of a battery of isometric / isotonic exercises on the maintenance of muscle composition and function for swallowing in Head / Neck Cancer patients undergoing chemo-radiation therapy.
Status | Completed |
Enrollment | 58 |
Est. completion date | April 2005 |
Est. primary completion date | July 2004 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 21 Years to 90 Years |
Eligibility |
Inclusion Criteria: - Head / neck cancer of the oropharyngeal or adjacent regions, confirmed by clinical history and exam, with positive cross sectional imaging studies and histopathological biopsy excluding other pathology. - Planned to undergo external beam radiation therapy, - No previous history of nonoral feeding for cancer related illness, - Able to undergo MRI procedures. - Physician / patient agreement to participate Exclusion Criteria: - Planned surgical intervention - Existence of a co-existing neurological or medical disorder known to cause dysphagia - Prior radiotherapy or surgery to the head / neck region that could contribute to dysphagia. - Previous swallowing therapy within four weeks of randomization |
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Investigator, Outcomes Assessor), Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
United States | University of Florida, Health Science Center | Gainesville | Florida |
Lead Sponsor | Collaborator |
---|---|
University of Florida | Florida Department of Health |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Oropharyngeal muscle volume and signal intensity measured by T2 weighted MRI | Baseline, 6 weeks( end of CRT), 6 months(following CRT) | No | |
Primary | Level of functional swallowing ability- measured by functional eating score (FOIS), clinical swallowing score, videoendoscopy and videofluoroscopic evaluation | Baseline, 6 week(end of CRT), 6 months(following CRT) | No | |
Primary | Patient perception of swallowing ability | Baseline, 6 weeks (end of CRT), 6 months (following CRT) | No | |
Primary | Quality of Life | Baseline, 6 weeks (end of CRT), 6 months (following CRT) | No | |
Secondary | Taste perception | Baseline, 6 weeks (end of CRT), 6 months (following CRT) | No | |
Secondary | Perception of smell | Baseline, 6 weeks (end of CRT), 6 months (following CRT) | No | |
Secondary | Salivation rates | Baseline, 6 weeks (end of CRT), 6 months (following CRT) | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT00670553 -
A Phase I Study of LBH589 (Panobinostat) in Combination With External Beam Radiotherapy for the Treatment of Prostate Cancer, Esophageal Cancer and Head and Neck Cancer
|
Phase 1 | |
Completed |
NCT03799380 -
DRIHNC - Dehydration Reduction in Head & Neck Cancer
|
N/A | |
Completed |
NCT03157674 -
Real-World Evidence and Treatment Patterns: Head and Neck Cancer
|
||
Completed |
NCT00565721 -
A Proof-of-concept Study to Assess the Ability of [18F]AH-111585 PET Imaging to Detect Tumours and Angiogenesis
|
Phase 2 | |
Completed |
NCT00935961 -
RAD001 (Everolimus) + Docetaxel + Cisplatin as Induction Chemotherapy in Patients With Local-Regional Advanced Head and Neck Cancer
|
Phase 1 | |
Recruiting |
NCT03065062 -
Study of the CDK4/6 Inhibitor Palbociclib (PD-0332991) in Combination With the PI3K/mTOR Inhibitor Gedatolisib (PF-05212384) for Patients With Advanced Squamous Cell Lung, Pancreatic, Head & Neck and Other Solid Tumors
|
Phase 1 | |
Completed |
NCT01268579 -
Pharmacodynamic Effects of Ribavirin in Patients With Tonsil and/or Base of Tongue Squamous Cell Carcinoma
|
N/A | |
Completed |
NCT03712397 -
Nanoliposomal Irinotecan in Head & Neck and Esophagus After Prior Platinum-based Chemotherapy or Chemoradiotherapy
|
Phase 2 | |
Completed |
NCT04040166 -
Carotid PET/MRI With DOTATATE in Patients Post Head and Neck Radiation Therapy
|
N/A | |
Completed |
NCT00736619 -
Weekly Nanoparticle Albumin-Bound Paclitaxel (Abraxane) + Weekly Cetuximab + Radiation Therapy (IMRT, Intensity-Modulated Radiation Therapy) in Patients With Stage III-IVB Head and Neck Squamous Cell Carcinoma (HNSCC)
|
Phase 1 | |
Completed |
NCT02375958 -
PCA062 in pCAD-positive Tumors.
|
Phase 1 |